Study guide

6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity

Certified Hospice and Palliative Nurse CHPN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise

2 Chapter 2: Assessment, Goals, and Care Planning

2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions

3 Chapter 3: Life-Limiting Disease Progression I

3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression

4 Chapter 4: Disease Progression II and Imminent Death

4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death

5 Chapter 5: Pain Assessment

5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience

6 Chapter 6: Pharmacologic Pain Management

6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes

7 Chapter 7: Nonpharmacologic Pain and Opioid Safety

7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation

8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms

8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions

9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms

9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms

10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms

10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden

11 Chapter 11: Advance Care Planning, Benefits, and Safety

11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional

12 Chapter 12: Communication, Culture, and Psychosocial Support

12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation

13 Chapter 13: Caregiver Education and Medication Management

13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services

14 Chapter 14: Grief, Death, and End-of-Life Ethics

14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life

15 Chapter 15: Medicare Hospice Compliance and National Standards

15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines

16 Chapter 16: Legal, Professional Practice, Quality, and Policy

16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends

6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity

Key Takeaways Explain This Topic AI

Acetaminophen has a true analgesic ceiling; the labeled adult maximum is 4,000 mg/24 h, many hospice protocols cap at 3,000 mg, and combination opioid tablets can hide a hepatotoxic load.

NSAIDs help prostaglandin-driven bone and inflammatory pain but carry gastrointestinal, renal, and platelet risks that are magnified in dying, dry, thrombocytopenic, or steroid-treated patients.

The WHO analgesic ladder is a historical intensity frame; current CHPN-level practice is mechanism-based and starts a strong opioid for moderate-to-severe cancer pain rather than lingering on codeine or tramadol.

Morphine is typically first-line when GFR is adequate; hydromorphone is a common rotation when morphine metabolites accumulate.

Avoid meperidine because of normeperidine seizures, avoid mixed agonist-antagonists in patients already on pure mu agonists, treat codeine as CYP2D6-unreliable, and treat tramadol as a seizure and SSRI interaction risk.

Last updated: August 2026

6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity

Pharmacologic pain management is the highest-yield judgment-and-math cluster on CHPN Domain 2 (Patient Care: Pain Management). Exam items almost never ask you to recite a drug class in isolation. They give a pain mechanism, a severity, a creatinine, and a current list, then ask which order you would question or which first-line opioid is appropriate. This section is selection . Titration lives in 6.3. Equianalgesic conversion lives in 6.4.

The WHO ladder is history; mechanism-based selection is current practice

The World Health Organization (WHO) analgesic ladder (1986, later revised) remains a useful intensity frame: mild pain is treated with a non-opioid plus or minus an adjuvant; moderate pain historically moved to a so-called weak opioid; severe pain moved to a strong opioid. Recognize that language. Do not treat the ladder as a mandatory three-week stay on each step.

Current hospice and palliative practice, consistent with NCCN Adult Cancer Pain guidance, is mechanism-based and severity-based :

Moderate-to-severe cancer pain is treated with a strong opioid . Lingering on codeine or tramadol because Step 2 is unfinished undertreats.

Bone and inflammatory pain often need an NSAID or corticosteroid in addition to an opioid.

Neuropathic pain needs an adjuvant (Section 6.2) in addition to an opioid when pain is severe.

Non-opioids and adjuvants are add-ons. They are not a moral substitute for opioids when pain is severe.

The three WHO administration slogans still apply at the bedside: by the mouth when the gut works, by the clock for continuous pain, and by the individual .

Acetaminophen: ceiling effect and hepatotoxicity

Acetaminophen is a non-opioid analgesic and antipyretic. It has a ceiling : once you are at an effective dose (often 650–1,000 mg), more milligrams do not buy more analgesia. They only buy hepatotoxicity. The labeled adult maximum is 4,000 mg in 24 hours in a well-nourished adult without liver disease. Many hospice protocols cap at 3,000 mg/day . Patients with malnutrition, prolonged fasting, heavy alcohol use, or extensive hepatic metastases often need 2,000 mg/day or less .

Hospice-specific traps:

Combination tablets (hydrocodone/acetaminophen or oxycodone/acetaminophen) hide acetaminophen. Titrating the opioid by giving more combination tablets can blow past the acetaminophen ceiling while pain remains 7/10. When opioid need rises, switch to a single-entity opioid and keep acetaminophen as a separately counted drug.

Dying patients are often glutathione-depleted. The toxic metabolite NAPQI is more dangerous in cachexia and poor intake.

Acetaminophen does not treat prostaglandin-driven bone pain as well as an NSAID. It is a reasonable co-analgesic for mild nociceptive pain or fever, not a complete plan for pathologic fracture pain.

NSAIDs for bone and inflammatory pain

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, ketorolac, and celecoxib inhibit cyclooxygenase and prostaglandin synthesis. Osteolytic bone metastases generate prostaglandins; that is why an NSAID can drop bone pain in a way acetaminophen will not. Short-course parenteral ketorolac is sometimes used for a severe inflammatory flare when the platelet count and glomerular filtration rate (GFR) allow it.

In dying patients the risks are concrete, not theoretical.

Risk Why it is worse in hospice Exam action

Gastrointestinal bleeding or ulcer Mucosal prostaglandin loss; worse with corticosteroids, anticoagulants, or prior ulcer Question the NSAID; do not combine blindly with dexamethasone

Renal hypoperfusion Afferent arteriolar prostaglandin preserves GFR when the patient is dry Avoid in oliguria, rising creatinine, or diuretic plus ACE-inhibitor stacking

Platelet inhibition COX-1 blockade (less with celecoxib, not zero systemic risk) Avoid in thrombocytopenia, active bleeding, or an imminent invasive procedure

If an NSAID is unsafe, dexamethasone may still treat inflammatory and bone pain (Section 6.2). An NSAID is never a reason to withhold a strong opioid for severe cancer pain.

Strong opioids: morphine first when the kidneys are acceptable

Morphine is the CHPN reference strong opioid: inexpensive, available as oral immediate-release (IR), oral extended-release (ER), concentrated oral solution, subcutaneous, intravenous, and rectal. It is typically first-line when renal function is adequate .

Morphine is metabolized to morphine-6-glucuronide (M6G) , which is analgesic, and morphine-3-glucuronide (M3G) , which is neuroexcitatory. Both accumulate when GFR falls. The exam picture of morphine in renal failure is myoclonus, hyperalgesia, delirium, or seizures , not a cue to give more morphine.

Oxycodone is a strong oral mu agonist when the oral route is intact. It has fewer glucuronide problems than morphine but is not risk-free in severe renal failure.

Hydromorphone is potent, available oral and parenteral, and is a common rotation target when morphine neurotoxicity or renal impairment appears. It still has a 3-glucuronide metabolite. It is better than morphine in moderate renal impairment, not a free pass in anuria.

Hydrocodone in U.S. hospice is often paired with acetaminophen. Treat it as adequate for some moderate pain, then abandon the combination product once acetaminophen milligrams — not pain — become the limiting factor.

Drugs the exam expects you to stop, not start

Meperidine is not a hospice opioid. Its metabolite normeperidine accumulates, especially when kidneys fail, and causes tremor, myoclonus, and seizures . It is the wrong answer for chronic cancer pain, for renal failure, and for using something short-acting solely because the patient is dying.

Mixed agonist-antagonists (nalbuphine, pentazocine, butorphanol) compete at the mu receptor. In a patient already on a pure mu agonist (morphine, oxycodone, hydromorphone, fentanyl), they can precipitate withdrawal and reverse analgesia. Do not stack them as safer breakthrough on a morphine regimen.

Codeine is a prodrug. CYP2D6 poor metabolizers form little morphine and get negligible analgesia; ultra-rapid metabolizers can get unexpected toxicity. Codeine is a poor primary plan for hospice-level cancer pain.

Tramadol is a weak mu agonist plus a serotonin/norepinephrine reuptake inhibitor. It lowers the seizure threshold and can precipitate serotonin syndrome with SSRIs, SNRIs, MAOIs, or other serotonergic drugs. It has a ceiling and is not a substitute for morphine in severe cancer pain.

Selection table

Clinical picture Prefer Avoid or question

Mild nociceptive pain, organs acceptable Acetaminophen, with or without an NSAID Exceeding the acetaminophen ceiling

Bone or inflammatory pain; platelets and GFR acceptable NSAID plus an opioid matched to severity NSAID plus steroid plus anticoagulant with no plan

Moderate-to-severe cancer pain, GFR adequate Morphine around-the-clock plus IR rescue Codeine trial, meperidine, tramadol as sole therapy

Severe pain, falling GFR, or morphine myoclonus Hydromorphone (or specialist fentanyl or methadone) More morphine

  • Already on morphine or oxycodone Titrate the same pure agonist Nalbuphine or pentazocine boost
  • Known CYP2D6 poor metabolizer Morphine or hydromorphone Codeine; be cautious with tramadol
  • Worked selection example

A 72-year-old with metastatic prostate cancer reports 7/10 aching hip pain. Creatinine is 0.9 mg/dL. He takes acetaminophen 1,000 mg four times daily (already 4,000 mg) plus hydrocodone/acetaminophen 5 mg/325 mg, two tablets every 4 hours as needed. If he takes six combination doses, that is another 3,900 mg of acetaminophen. He also takes sertraline.

Stop counting combination tablets. He is over the acetaminophen ceiling. Severe bone pain needs a strong opioid — morphine IR and ER are appropriate because the kidneys are acceptable — plus consideration of an NSAID or dexamethasone for the bone mechanism. Do not add tramadol on sertraline. Do not start meperidine for short action.

Match severity × mechanism × organ function , not a calendar on the WHO ladder.

Loading diagram... CHPN analgesic selection by severity, mechanism, and organ function

Acetaminophen 24-hour milligram caps used in hospice teaching